Investigational DME agent nears phase II trial

iCo Therapeutics and JDRF, formerly the Juvenile Diabetes Research Foundation, have joined forces in a phase II clinical trial to investigate the investigational drug iCo-007 as a treatment for diabetic macular edema (DME).

Full Story →